# **Investment & NTA Update**

## 31 August 2025



#### **NGE Capital Summary**

ASX ticker	NGE
Share price (31 Aug 25)	\$1.220
Shares outstanding	34,303,223
Market cap	\$41.8m
NTA per share before tax	\$1.518
NTA per share after tax	\$1.624
NTA before tax	\$52.1m
NTA after tax	\$55.7m

#### Overview

NGE Capital Limited is an internally managed Listed Investment Company which allows investors to gain exposure to a concentrated, high conviction, actively managed portfolio of financial assets. NGE primarily focuses on listed ASX and international equities, with the aim of generating strong risk-adjusted returns over the medium to long term.

### Board & Management

David Lamm
Executive Chairman &
Chief Investment Officer

Adam Saunders
Executive Director &
Portfolio Manager

**Ilan Rimer**Non-Executive Director

Leslie Smith
Company Secretary &
Chief Financial Officer

#### **Contact Details**

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 +61 3 9648 2290

admin@ngecapital.com.au

www.ngecapital.com.au

#### Net Tangible Assets Per Share

	31 Aug 2025	31 Jul 2025
NTA per share before tax	\$1.518	\$1.427
NTA per share after tax	\$1.624	\$1.533

#### NTA Per Share Performance Summary

1 month	Year-to	Last 12	Since ir	nception <sup>1</sup>
	-date	months	(p.a.)	(cum.)
6.4%	17.9%	17.4%	13.3%	197.6%

Note: Returns are net of all expenses. FYE 31 December.

1 From 30 Nov 2016, the date on which NGE became a LIC.

### Portfolio Composition

Company	Ticker	% of NTA
Yellow Cake plc	LSE:YCA	13.8%
Industrial Logistics Properties	NAS:ILPT	8.1%
MLG Oz	ASX:MLG	7.6%
Pioneer Credit	ASX:PNC	7.5%
Cash Converters International	ASX:CCV	7.2%
Jupiter Mines	ASX:JMS	6.5%
K92 Mining Inc.	TSX:KNT	6.3%
Carnarvon Energy	ASX:CVN	6.3%
Metals X	ASX:MLX	6.1%
Sprott Physical Uranium Trust	TSX:U.UN	5.4%
Embark Early Education	ASX:EVO	4.2%
Northern Ocean Ltd.	OSL:NOL	3.9%
Capricorn Energy PLC	LSE:CNE	3.7%
Indiana Resources	ASX:IDA	2.6%
Danakali	NSX:DNK	1.7%
Achieve Life Sciences	NAS:ACHV	1.4%
Net cash and other		8%
Total		100%

### **Unrecognised Tax Losses**

The Company has ~\$22 million of Australian unused and unrealised losses available as at 31 August 2025. In the aggregate these losses equate to a potential future tax benefit of ~\$5m or ~\$0.16 per share (of which only ~\$3.7m or ~\$0.107 per share is recognised in our after tax NTA). The Company has received tax advice that these losses are available to be offset against future tax liabilities so long as NGE continues to satisfy the continuity of ownership test as set out in Divisions 165 and 166 of the Income Tax Assessment Act 1997 (Cth).

• • •

# Commentary

### 31August 2025

During August and subsequent to month end we made the following notable portfolio changes:

we added to our holding in Carnarvon Energy Limited
(ASX:CVN), a position we initiated in late July and reveal now
for the first time. We held ~32.6m shares at month end, and
currently hold 35.0m shares.

We think Carnarvon's assets, comprising cash, a 19.9% shareholding in **Strike Energy Limited (ASX:STX)**<sup>1</sup>, a 10% stake in the world-class Dorado oil and gas development project offshore WA, Dorado development free carry, a 20% stake in the Pavo oil find, and interests in highly prospective exploration assets could be worth ~25-40cps in aggregate on a present value basis and net of corporate costs and interest income. This compares very favourably to the month end share price of 10c.

Our valuation range is driven by uncertainty around the development timeline for Dorado as operator **Santos Limited (ASX:STO)**, which holds an 80% stake in the project, has dragged its feet on advancing the project through FEED to FID. Santos was unable to sell down a portion of its interest in Dorado during 2024 in an effort to reduce its share of the upfront capex cost — a hefty ~US\$2bn on a 100% basis (Santos share ~US\$1.6bn), though there is potential for a lower cost depending on project design. In the meantime, Santos has been focused on other development projects in its portfolio and maintaining balance sheet discipline.

Following a board reshuffle in December 2023, instigated by Nero Resource Fund and Collins St Asset Management, Carnarvon has focused on preserving balance street strength, reducing corporate and administrative costs, and maximising value from the existing resource base.

As a result Carnarvon also tried in 2024 to shop its interest in Dorado/Pavo to prospective buyers, hiring JP Morgan to explore "alternative transactions to accelerate value realisation". Carnarvon was out of luck, and when Dorado FID was pushed out yet again – from "FID in 2024" to "being FID-ready by end of 2024" to "FID expected in 2025", to now FID being deferred with no definitive timeline – investor patience wore thin and the share price sold off. The decision to cancel a proposed 7cps capital return in favour of making an investment in Strike Energy, which looks to be a somewhat risky bet in our view, has further dampened investor interest

in Carnarvon.

Derisking Carnarvon's investment in Strike Energy in the short-term will depend on drilling success at the Walyering West-1 exploration well (expected 1H 2026), improved flowrates following the workover of the South Erregulla-1 well (expected this quarter), and successful commissioning of the under-construction 85MW South Erregulla Peaking Gas Power Station (target completion 1 Oct 2026).

Near-term catalysts that could have positive implications for the Dorado development timeline include a one-well drilling campaign planned for mid-2026 targeting the northern region of Carnarvon's exploration permits, and progress on the XRG/ADNOC consortium bid for Santos.

At our average entry price of ~10.46c we are effectively paying for Carnarvon's cash balance and shareholding in Strike Energy, whilst getting the Dorado stake, development free carry, interest in the Pavo discovery and highly prospective exploration assets for free. In spite of recent setbacks we think Carnarvon offers a very attractive asymmetric investment return profile for the patient investor;

- we trimmed our holdings in Cash Converters International Limited (ASX:CCV) and Pioneer Credit Limited (ASX:PNC) on the back of strong share price performance as both companies reported solid FY25 results. We held ~11.0m shares of CCV and ~6.5m shares of PNC at month end. Subsequent to month end we have locked in additional profits in CCV and currently hold 8.9m shares; and
- we increased our holding in Achieve Life Sciences, Inc. (NAS:ACHV) to 300k shares after the company announced on 3 September that the US FDA has accepted ACHV's cytisinicline New Drug Application for a new treatment for smoking cessation in adults. The FDA's review has now formally begun, and a decision is expected by 20 June 2026.

As we noted in our 2025 AGM presentation, the FDA's acceptance of an NDA for filing "can often be the catalyst to corporate actions even prior to completion of FDA's review". A sale, partnership, licensing agreement or funding agreement could potentially see ACHV's shares worth 2-5x more on a fully diluted basis, though downside risk remains high.



 $<sup>^{\</sup>rm 1}$  Following forthcoming settlement of Tranche 2.

# Commentary

## 31August 2025

•••



David LammAdam SaundersChief Investment OfficerPortfolio Manager



**IMPORTANT INFORMATION:** While management of NGE Capital Limited (NGE Capital) have taken every effort to ensure the accuracy of the material in this document, the material is provided for information purposes only. No representation or warranty, express or implied, is or will be made by NGE Capital or its officers, directors, employees or advisers as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in, or implied by, this document, or as to the reasonableness of any assumption, forecasts, prospects or returns contained in, or implied by, this document or any part of it. This document does not constitute investment, legal, taxation or other advice and the document does not account your investment objectives, financial situation nor particular needs. You are responsible for forming your own opinions and conclusions on such matters and should make your own independent assessment of the information contained in, or implied by, this document and seek independent professional advice in relation to such information and any action taken on the basis of the information. This document is not, and does not constitute advice or an offer to sell or the solicitation, invitation or recommendation to purchase any securities that are referred to in this document.